Who are tegafur-uracil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Fluorouracil Injection, 5-Fluorouracile, 5-Fluouracil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tegafur-uracil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

tegafur-uracil — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

tegafur-uracil (tegafur-uracil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite; 5-fluorouracil prodrug. Area: Oncology.

marketed Antimetabolite; 5-fluorouracil prodrug Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

tegafur-uracil (tegafur-uracil) — Yokohama City University. Tegafur-uracil is a combination prodrug that is converted to fluorouracil in the body to inhibit thymidylate synthase and disrupt DNA synthesis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
tegafur-uracil TARGET	tegafur-uracil	Yokohama City University	marketed	Antimetabolite; 5-fluorouracil prodrug	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Fluorouracil Injection	Fluorouracil Injection	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	marketed	Antimetabolite	Thymidylate synthase
5-Fluorouracile	5-Fluorouracile	Groupe Oncologie Radiotherapie Tete et Cou	marketed	Antimetabolite; pyrimidine analog	Thymidylate synthase; RNA and DNA incorporation
5-Fluouracil	5-Fluouracil	Hoffmann-La Roche	marketed	Antimetabolite	Thymidylate synthase; RNA and DNA incorporation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite; 5-fluorouracil prodrug class)

Liaoning Cancer Hospital & Institute · 1 drug in this class
Yokohama City University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tegafur-uracil — Competitive Intelligence Brief. https://druglandscape.com/ci/tegafur-uracil. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing